Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is the issuer in a Schedule 13G in which four reporting persons each report the same 1,914,788-share position, equal to 9.9% of the common stock. RA Capital Healthcare Fund, L.P. directly holds the shares; RA Capital Management, L.P. serves as the Fund’s investment adviser. Each cover page lists 1,914,788 shares of shared voting and dispositive power. The reported percentage is based on 19,341,293 Corbus shares outstanding as of August 4, 2026.
The Fund says it delegated voting and investment power to RA Capital and disclaims beneficial ownership because it may not revoke that delegation on less than 61 days’ notice. Peter Kolchinsky and Rajeev Shah, as RA Capital managers, may be deemed beneficial owners; RA Capital, Kolchinsky and Shah disclaim beneficial ownership except for determining their obligations under Section 13(d). The reporting persons expressly disclaim status as a group.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) director Ben Yong sold 2,000 shares of common stock on September 14, 2026 in an open-market transaction at a weighted average price of $7.84 per share, under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following the sale, he held 9,383 shares in total, including 3,800 unvested RSUs subject to vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported positive topline results from its CANYON-1 Phase 1b trial of oral obesity drug candidate CRB-913. The 16‑week, double-blind, placebo-controlled study enrolled 254 obese, non-diabetic adults across 15 U.S. sites, testing 20 mg, 40 mg and 60 mg once-daily doses versus placebo.
The 60 mg dose achieved a 5.0% mean weight loss at 12 weeks versus 0.0% for placebo, with no evidence of plateauing. Among participants completing 60 mg, 44.4% lost at least 5% of baseline weight, 6.7% lost more than 7.5%, and the maximum loss was 13.4%. CRB-913 was generally safe and well tolerated; treatment-emergent psychiatric events were mild to moderate with no suicidality and only one transient depressive symptom in 188 treated participants, and gastrointestinal events were mild or moderate and appeared less frequent than those reported for oral GLP‑1 drugs in cross‑trial comparisons.
The CRB-913 data were selected for a late-breaking presentation at ObesityWeek 2026. Corbus plans to engage the FDA on the development plan and expects to initiate a Phase 2 monotherapy obesity study in the first half of 2027, while also evaluating CRB‑913 combinations with GLP‑1 therapies.
Corbus Pharmaceuticals Holdings, Inc. granted its Chief Medical Officer, Nicacio Leonardo Viana, new equity awards on August 16, 2026. He received 191,676 stock options to buy common stock at an exercise price of $10.09 per share, expiring on August 16, 2036. Under the company’s 2026 Inducement Award Plan, 25% of this option vests on August 3, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting September 3, 2027. He was also granted 58,333 restricted stock units (RSUs), settling in common shares, vesting 25% on each of the first four anniversaries beginning August 16, 2027, with specified prorated vesting and forfeiture terms if his service is terminated without cause after the first vesting date.
Citadel-affiliated entities and Kenneth Griffin report their equity position in Corbus Pharmaceuticals Holdings, Inc. The group reports beneficial ownership of 206,354 Shares of common stock, representing 1.1% of the outstanding Shares, based on 18,527,795 Shares outstanding as of May 8, 2026 as cited from Corbus’s Form 10-Q. Certain Citadel entities report 0 Shares and 0.0% ownership. Voting and dispositive authority over the 206,354 Shares is reported as shared among Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Mr. Griffin, with no sole voting or dispositive power reported.
Corbus Pharmaceuticals Holdings, Inc. Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 at an average price of $9.6294 per share in a direct open-market or private transaction. Following this trade, his direct holdings total 77,900 shares, which the footnote states include 58,300 unvested RSUs subject to a vesting schedule. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported selling 17,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0821 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Cohen holds 157,316 shares directly, including 138,049 unvested RSUs subject to vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported a sale of 12,000 shares of common stock on August 7, 2026. The shares were sold at a weighted average price of $10.0809 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Moran holds 84,694 shares directly, including 68,795 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. is establishing an at-the-market offering of its common stock under a shelf registration, allowing sales of up to $127,500,000 of shares from time to time through Jefferies LLC as sales agent. Jefferies may sell shares on Nasdaq under mutually agreed placement notices and will receive a 3% commission on gross proceeds, being deemed an underwriter for these transactions.
Assuming sales at $9.40 per share, the company illustrates issuance of 13,563,829 shares, which, together with prior sales, would increase common shares outstanding from 18,671,498 as of June 30, 2026 to up to 32,974,034. Pro forma as adjusted net tangible book value would rise to $228.7 million, or $6.94 per share, implying dilution of $2.46 per share to new investors relative to the assumed offering price. Corbus plans to use net proceeds primarily to advance its clinical pipeline, including CRB-701 in oncology and CRB-913 in obesity, and for general corporate purposes such as pre-clinical programs, working capital, potential acquisitions or investments, debt reduction and capital expenditures. The company highlights risks of share price volatility, potential dilution from existing equity awards and warrants, and uncertainty about the timing, pricing and total number of shares ultimately sold under the program.
An affiliate of CRBP has filed notice of intent to sell up to 12,000 shares of common stock through broker Stifel Nicolaus & Company Inc. on or after 08/07/2026 on the Nasdaq market, with an indicated aggregate market value of $120,971.00.
The shares relate to equity compensation in the form of Restricted Stock Units, including 7,317 shares tied to RSUs dated 02/12/2026 and 4,683 shares tied to RSUs dated 01/31/2026.